Efficacy and safety of clobazam in the additional treatment of refractory epilepsy in children： meta-analysis of single-group rate

TU Caixia; REN Danyang; SHEN Jianling; LI Yunwei; YANG Yanming; YAN Aihua; LI Lin; LI Huiying

doi:10.6039/j.issn.1001-0408.2024.15.16

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of clobazam in the additional treatment of refractory epilepsy in children： meta-analysis of single-group rate

更新时间：2024-08-11

- Efficacy and safety of clobazam in the additional treatment of refractory epilepsy in children： meta-analysis of single-group rate
- ZHONGGUO YAOFANG Vol. 35, Issue 15, Pages: 1893-1898(2024)
- 作者机构：
  
  昆明市儿童医院（昆明医科大学附属儿童医院）药剂科，昆明　650228
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.15.16
  CLC： R971;R985;R969.3
- Published：15 August 2024，
  
  Received：19 January 2024，
  
  Revised：25 June 2024，
- 稿件说明：
扫描看全文
涂彩霞,任丹阳,沈建玲等.氯巴占附加治疗儿童难治性癫痫的有效性和安全性单组率的Meta分析 ^Δ[J].中国药房,2024,35(15):1893-1898.

TU Caixia,REN Danyang,SHEN Jianling,et al.Efficacy and safety of clobazam in the additional treatment of refractory epilepsy in children： meta-analysis of single-group rate[J].ZHONGGUO YAOFANG,2024,35(15):1893-1898.
涂彩霞,任丹阳,沈建玲等.氯巴占附加治疗儿童难治性癫痫的有效性和安全性单组率的Meta分析 ^Δ[J].中国药房,2024,35(15):1893-1898. DOI： 10.6039/j.issn.1001-0408.2024.15.16.

TU Caixia,REN Danyang,SHEN Jianling,et al.Efficacy and safety of clobazam in the additional treatment of refractory epilepsy in children： meta-analysis of single-group rate[J].ZHONGGUO YAOFANG,2024,35(15):1893-1898. DOI： 10.6039/j.issn.1001-0408.2024.15.16.

摘要

目的

探讨氯巴占附加治疗儿童难治性癫痫的有效性和安全性，为临床安全、合理用药提供参考。

方法

计算机检索PubMed、The Cochrane Library、Embase、中国知网、维普网、万方数据中有关氯巴占附加治疗儿童难治性癫痫的文献，检索时限为建库起至2023年11月。筛选文献、提取资料，并参考非随机对照试验的方法学评价指标质量评价工具对纳入的文献进行质量评价后，采用RevMan 5.3软件进行单组率的Meta分析和敏感性分析。

结果

共纳入18项单臂研究，共计1 424例患儿。结果显示，与加用氯巴占之前比，氯巴占附加治疗后，无癫痫发作（癫痫发作减少100%）的患儿占比经转换后为24%[95%CI（0.18，0.32），

＜0.000 01

]

；癫痫发作减少≥75%的患儿占比经转换后为32%[95%CI（0.25，0.40），

＜0.000 1

]

；癫痫发作减少≥50%的患儿占比为53%[95%CI（0.44，0.61），

＜0.000 01

]

；癫痫发作减少＜50%或无变化的患儿占比经转换后为35%[95%CI（0.24，0.49），

＝0.04

]

；癫痫发作增加的患儿占比经转换后为9%[95%CI（0.05，0.18），

＜0.000 01

]

。发生不良反应的患儿占比经转换后为31%[95%CI（0.23，0.40），

＜0.000 1

]

；因不良反应停用氯巴占的患儿占比经转换后为10%[95%CI（0.07，0.15），

＜0.000 01

]

；常见的不良反应为嗜睡、疲劳、行为改变等。敏感性分析显示，本研究所得结果较稳健。

结论

氯巴占是一种儿童难治性癫痫的有效附加治疗药物，但需警惕其不良反应。

Abstract

OBJECTIVE

To investigate the efficacy and safety of clobazam in the additional treatment of refractory epilepsy in children， and provide reference for clinically safe and rational drug use.

METHODS

The literatures about additional clobazam treatment for refractory epilepsy in children were searched from PubMed， The Cochrane Library， Embase， CNKI， VIP and Wanfang database during the inception to November 2023. After literature screening and data extraction， the quality of included literature was evaluated according to quality evaluation tool for methodological evaluation indicators of non-randomized controlled trial， and then meta-analysis of single-group rate and sensitivity analysis were performed by using RevMan 5.3 software.

RESULTS

Finally， 18 one-arm studies were included， with a total of 1 424 children. The results showed that compared with before additional treatment， the proportion of patients with seizures-free （proportion of patients with seizure reduction of 100%） was 24%[95%CI（0.18，0.32）

，

＜0.000 01

]

after conversion； the proportion of patients with seizure reduction ≥75% was 32%[95%CI（0.25，0.40），

＜0.000 1

]

after conversion； the proportion of patients with seizure reduction ≥50% was 53%[95%CI（0.44，0.61），

＜0.000 01

]

； the proportion of patients with seizure reduction ＜50% or no change was 35%[95%CI（0.24，0.49），

＝0.04

]

after conversion； the proportion of patients with seizure increase was 9%[95%CI（0.05，0.18），

＜0.000 01

]

after conversion. The proportion of patients with adverse reactions was 31%[95%CI（0.23，0.40），

＜0.000 1

]

after conversion； the proportion of patients with discontinuation due to adverse reactions was 10%[95%CI（0.07， 0.15），

＜0.000 01

]

after conversion. The common adverse drug reactions were drowsiness， fatigue and behavior change， etc. The results of the sensitivity analysis showed that the study was robust.

CONCLUSIONS

Clobazam is an effective additional therapy for refractory epilepsy in children， but its adverse effects should be vigilant.

关键词

氯巴占难治性癫痫儿童附加治疗Meta分析

Keywords

refractory epilepsychildrenadditional treatmentmeta-analysis

references

张波，张抒扬，许婷婷，等. 氯巴占治疗难治性癫痫专家共识：2022[J].协和医学杂志，2022，13（5）：768-782.

ZHANG B，ZHANG S Y，XU T T，et al. Expert consensus on clobazam in the treatment of refractory epilepsy：2022[J]. Med J Peking Union Med Coll Hosp，2022，13（5）：768-782.

KAMAŞAK T，SERDAROĞLU E，YILMAZ Ö，et al. The effectiveness and tolerability of clobazam in the pe- diatric population：adjunctive therapy and monotherapy in a large-cohort multicenter study[J]. Epilepsy Res，2022，184：106963.

UZUNHAN T A，GOR Z. Efficacy and side effect profile of clobazam in children with different etiologies of epilepsy from a single center[J]. Sisli Etfal Hastan Tip Bul，2020，54（2）：236-244.

ARYA R，GIRIDHARAN N，ANAND V，et al. Clobazam monotherapy for focal or generalized seizures[J]. Cochrane Database Syst Rev，2018，7（7）：CD009258.

BRESNAHAN R，MARTIN-MCGILL K J，WILLIAMSON J，et al. Clobazam add-on therapy for drug-resistant epilepsy[J]. Cochrane Database Syst Rev，2019，10（10）：CD004154.

DEVI N，MADAAN P，AMEEN R，et al. Short-term and long-term efficacy and safety of antiseizure medications in Lennox-Gastaut syndrome：a network meta-analysis[J]. Seizure，2022，99：164-175.

ZHANG L L，WANG J，WANG C Z. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome：a systematic review and network meta-analysis[J]. Dev Med Child Neurol，2022，64（3）：305-313.

CONRY J A，NG Y T，PAOLICCHI J M，et al. Clobazam in the treatment of Lennox-Gastaut syndrome[J]. Epilepsia，2009，50（5）：1158-1166.

NG Y T，CONRY J A，DRUMMOND R，et al. Rando- mized，phase Ⅲ study results of clobazam in Lennox-Gastaut syndrome[J]. Neurology，2011，77（15）：1473-1481.

SHETH R D，RONEN G M，GOULDEN K J，et al. Clobazam for intractable pediatric epilepsy[J]. J Child Neurol，1995，10（3）：205-208.

易小琦，邓红彬，李龙浩，等. PD-1/PD-L1抑制剂用于膀胱癌新辅助治疗疗效和安全性的单组率Meta分析[J]. 中国药房，2023，34（18）：2256-2262.

YI X Q，DENG H B，LI L H，et al. Efficacy and safety of PD-1/PD-L1 inhibitors for neoadjuvant treatment of bladder cancer：meta-analysis of single-group rates[J]. China Pharm，2023，34（18）：2256-2262.

CAMPOS P. Clobazam use in refractory epilepsies in children[J]. Arq Neuropsiquiatr，1993，51（1）：66-71.

DA SILVEIRA M R，MONTENEGRO M A，FRANZON R C，et al. Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy[J]. Arq Neuro- psiquiatr，2006，64（3B）：705-710.

FARRELL K. Benzodiazepines in the treatment of children with epilepsy[J]. Epilepsia，1986，27（Suppl. 1）：S45-S52.

HAHN J，LEE H，KANG H C，et al. Clobazam as an adjunctive treatment for infantile spasms[J]. Epilepsy Behav，2019，95：161-165.

JAN M M，SHAABAT A O. Clobazam for the treatment of intractable childhood epilepsy[J]. Saudi Med J，2000，21（7）：622-624.

KALRA V，SETH R，MISHRA D，et al. Clobazam in refractory childhood epilepsy[J]. Indian J Pediatr，2010，77（3）：263-266.

KLEHM J，THOME-SOUZA S，SÁNCHEZ FERNÁNDEZ I，et al. Clobazam：effect on frequency of seizures and safety profile in different subgroups of children with epilepsy[J]. Pediatr Neurol，2014，51（1）：60-66.

MILLS J K，LEWIS T G，MUGHAL K，et al. Retention rate of clobazam，topiramate and lamotrigine in children with intractable epilepsies at 1 year[J]. Seizure，2011，20（5）：402-405.

MUNN R，FARRELL K. Open study of clobazam in refractory epilepsy[J]. Pediatr Neurol，1993，9（6）：465-469.

SHIMIZU H，ABE J，FUTAGI Y，et al. Antiepileptic effects of clobazam in children[J]. Brain Dev，1982，4（1）：57-62.

SILVA R C，MONTENEGRO M A，GUERREIRO C A， et al. Clobazam as add-on therapy in children with epileptic encephalopathy[J]. Can J Neurol Sci，2006，33（2）：209-213.

TÜRKODĞAN D，ÖZTÜRK G. CLB add-on treatment in patients with epileptic encephalopathy：a single center experience with long-term follow-up[J]. Acta Neurol Belg，2022，122（1）：51-57.

WEINSTOCK A，AGARWAL N，FAROOQ O，et al. Evaluation of the effects of clobazam on seizure control and quality of life in children with Lennox-Gastaut syndrome：a pilot study[J]. J Child Neurol，2019，34（8）：432-439.

MUNN R，CAMFIELD P，CAMFIELD C，et al. Clobazam for refractory childhood seizure disorders：a valuable supplementary drug[J]. Can J Neurol Sci，1988，15（4）：406-408.

KEENE D L，WHITING S，HUMPHREYS P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood[J]. Can J Neurol Sci，1990，17（3）：317-319.

PERRY M S，BAILEY L，MALIK S，et al. Clobazam for the treatment of intractable epilepsy in children[J]. J Child Neurol，2013，28（1）：34-39.

FLEEMAN N，BRADLEY P M，PANEBIANCO M，et al. Care delivery and self-management strategies for children with epilepsy[J]. Cochrane Database Syst Rev，2022，4（4）：CD006245.

SULTANA B，PANZINI M A，VEILLEUX CARPENTIER A，et al. Incidence and prevalence of drug-resistant epilepsy：a systematic review and meta-analysis[J]. Neuro- logy，2021，96（17）：805-817.

SATISHCHANDRA P，RATHORE C，APTE A，et al. Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes：an Indian experience[J]. Epilepsy Behav，2022，130：108671.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of probiotics in the treatment of nonalcoholic fatty liver disease： a meta-analysis

Meta-analysis of Fuzheng jiedu therapy of traditional Chinese medicine in the treatment of advanced non-small cell lung cancer

Meta-analysis on efficacy and safety of thalidomide combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia

Effects of ivabradine on vascular endothelial function in patients with coronary artery disease： a meta-analysis

Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol

Related Author

LU Fenping

XING Guangyan

HU Shiping

LI Zhuo

QIAO Ling

WANG Yijie

WANG Wei

LI Xiaojing

Related Institution

Beijing University of Chinese Medicine

Shenzhen Hospital， Beijing University of Chinese Medicine

TCM Cancer Treatment Center， Chongqing University Cancer Hospital

Dept. of Hematology， Shanghai Municipal Hospital of Traditional Chinese Medicine， Shanghai University of Traditional Chinese Medicine

Dept. of Cardiology， Nanjing Drum Tower Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰